These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27242211)

  • 1. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
    Lasolle H; Raverot G
    Presse Med; 2016 Jun; 45(6 Pt 2):e211-6. PubMed ID: 27242211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
    Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
    Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
    Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide: a novel treatment for pituitary carcinoma.
    Lim S; Shahinian H; Maya MM; Yong W; Heaney AP
    Lancet Oncol; 2006 Jun; 7(6):518-20. PubMed ID: 16750503
    [No Abstract]   [Full Text] [Related]  

  • 10. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pituitary neoplasms with temozolomide: A review.
    Marucci G
    Cancer; 2011 Sep; 117(17):4101-2; author reply 4102. PubMed ID: 21387270
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
    Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
    Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
    Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
    Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
    McCormack AI; Wass JA; Grossman AB
    Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How effective is temozolomide for treating pituitary tumours and when should it be used?
    Halevy C; Whitelaw BC
    Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
    Bode H; Seiz M; Lammert A; Brockmann MA; Back W; Hammes HP; Thomé C
    Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):760-3. PubMed ID: 20496311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
    Syro LV; Rotondo F; Ortiz LD; Kovacs K
    Endocr Relat Cancer; 2018 Aug; 25(8):T159-T169. PubMed ID: 29535142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.